English
| dc.contributor.author | Özel, HE | |
| dc.contributor.author | Özdogan, F | |
| dc.contributor.author | Gürgen, SG | |
| dc.contributor.author | Esen, E | |
| dc.contributor.author | Genç, S | |
| dc.contributor.author | Selçuk, A | |
| dc.date.accessioned | 2024-07-18T11:56:00Z | |
| dc.date.available | 2024-07-18T11:56:00Z | |
| dc.description.abstract | CAMBRIDGE UNIV PRESS | |
| dc.identifier.issn | 1748-5460 | |
| dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/6659 | |
| dc.language.iso | Article | |
| dc.publisher | 0022-2151 | |
| dc.subject | Objective: This study aimed to compare the efficacies of intratympanic dexamethasone and methylprednisolone in preventing in cisplatin-induced ototoxicity in rats. Methods: Experimental groups of rats (n = 8 each) received intratympanic isotonic saline, intraperitoneal cisplatin and intratympanic isotonic saline, intraperitoneal cisplatin and intratympanic dexamethasone, or intraperitoneal cisplatin and intratympanic methylprednisolone. Distortion product otoacoustic emission thresholds were compared on days 0 and 10 in all rats, and correlations between drug effects and changes in cochlear histology were evaluated. Results: Distortion product otoacoustic emission thresholds were comparable in groups III and IV (p > 0.05). Significant protection against cisplatin-induced ototoxicity was seen in groups III and IV compared with group II (p < 0.05). Dexamethasone and, to a lesser extent, methylprednisolone protected against cellular apoptosis in cisplatin-induced ototoxicity. Conclusion: Dexamethasone (and possibly methylprednisolone) may be clinically useful as an intratympanic chemopreventive agent to treat cisplatin ototoxicity. Future clinical studies should investigate the use of dexamethasone for this purpose in adult patients. | |
| dc.title | English | |
| dc.type | N-ACETYLCYSTEINE | |
| dc.type | HEARING-LOSS | |
| dc.type | PREVENTION | |
| dc.type | INJECTIONS | |
| dc.type | APOPTOSIS | |
| dc.type | MODEL |